PE20061335A1 - Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c - Google Patents
Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2cInfo
- Publication number
- PE20061335A1 PE20061335A1 PE2006000414A PE2006000414A PE20061335A1 PE 20061335 A1 PE20061335 A1 PE 20061335A1 PE 2006000414 A PE2006000414 A PE 2006000414A PE 2006000414 A PE2006000414 A PE 2006000414A PE 20061335 A1 PE20061335 A1 PE 20061335A1
- Authority
- PE
- Peru
- Prior art keywords
- benzodioxin
- dihydro
- amine
- methyl
- benzodioxane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE BENZODIOXANO DE FORMULA (I), DONDE M ES 1 O 2; n ES 0 0 1; Ar ES FENILO, UN ANILLO CARBOCICLO ARILO O BICICLICO PARCIALMENTE INSATURADO DE 8 A 10 MIEMBROS, HETEROARILO MONOCICLICO DE 5 A 6 MIEMBROS QUE TIENE DE 1 A 4 HETEROATOMOS SELECCIONADOS DE NITROGENO, OXIGENO O AZUFRE, ENTRE OTROS; R1 ES R, CN, HALOGENO, OR, ENTRE OTROS; R ES H, ENTRE OTROS; R2 ES H, ALQUILO C1-C3, O(ALQUILO C1-C3), ENTRE OTROS; R3 Y R4 SON H O ALIFATICO C1-C6. SON COMPUESTOS PREFERIDOS: {[8-(2-FLUORFENIL)-2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL]METIL}AMINA, {[8-(2-CLOROFENIL)-2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL]METIL}AMINA, {[8-(2-METILFENIL)-2,3-DIHIDRO-1,4-BENZODIOXIN-2-IL]METIL}AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR 5-HT2C Y SON UTILES PARA EL TRATAMIENTO DE LA ESQUIZOFRENIA, OBESIDAD, DEPRESION, ENTRE OTRAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67388405P | 2005-04-22 | 2005-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061335A1 true PE20061335A1 (es) | 2006-12-29 |
Family
ID=36688044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000414A PE20061335A1 (es) | 2005-04-22 | 2006-04-21 | Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060241172A1 (es) |
EP (1) | EP1871759A1 (es) |
JP (1) | JP2008538575A (es) |
KR (1) | KR20080009295A (es) |
CN (1) | CN101218223A (es) |
AR (1) | AR054035A1 (es) |
AU (1) | AU2006239930A1 (es) |
BR (1) | BRPI0610046A2 (es) |
CA (1) | CA2605580A1 (es) |
CR (1) | CR9459A (es) |
GT (1) | GT200600159A (es) |
IL (1) | IL186835A0 (es) |
MX (1) | MX2007013151A (es) |
NI (1) | NI200700270A (es) |
NO (1) | NO20075623L (es) |
PE (1) | PE20061335A1 (es) |
RU (1) | RU2007139543A (es) |
TW (1) | TW200720266A (es) |
WO (1) | WO2006116158A1 (es) |
ZA (1) | ZA200709043B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
DK1530967T3 (da) * | 2003-11-13 | 2006-07-03 | Ferring Bv | Blisterpakning og dertil hörende fast dosisform |
AR049646A1 (es) * | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
ATE400565T1 (de) * | 2004-08-24 | 2008-07-15 | Janssen Pharmaceutica Nv | Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate |
GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
US20060258713A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Treatment of pain |
PE20061297A1 (es) * | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c |
CN101175740A (zh) * | 2005-04-22 | 2008-05-07 | 惠氏公司 | 二氢苯并呋喃衍生物和其用途 |
JP2008538573A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用 |
AU2006239910A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
TW200719886A (en) * | 2005-04-22 | 2007-06-01 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
AU2006239900A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
EP1874292A2 (en) * | 2005-04-24 | 2008-01-09 | Wyeth | Methods for modulating bladder function |
EP1881959A1 (en) * | 2005-05-20 | 2008-01-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
SE0600482L (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
CN101448492A (zh) * | 2006-03-24 | 2009-06-03 | 惠氏公司 | 治疗认知障碍和其它障碍的方法 |
AR060493A1 (es) * | 2006-04-18 | 2008-06-18 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano. procesos de obtencion. |
EP2742936A1 (en) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
JP2009537635A (ja) * | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
CL2007003044A1 (es) * | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
AR063373A1 (es) * | 2006-10-24 | 2009-01-21 | Wyeth Corp | Derivados de benzodioxano y sus usos |
US8399410B2 (en) | 2007-08-06 | 2013-03-19 | Allergan, Inc. | Methods and devices for desmopressin drug delivery |
JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
MX2010011498A (es) | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
US20110105462A1 (en) * | 2008-04-29 | 2011-05-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
KR20100135325A (ko) | 2008-04-29 | 2010-12-24 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 조절제 |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
NO2296686T3 (es) | 2008-05-21 | 2014-07-12 | ||
US8809385B2 (en) * | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
BR112013001430B1 (pt) | 2010-07-20 | 2018-02-06 | Bayer Cropscience Ag | Compostos, composição fungicida e método para controle de fungos fitopatogênicos de culturas |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
MX344516B (es) | 2010-12-21 | 2016-12-19 | Colgate Palmolive Co | Bifenoles halogenados como agentes antibacterianos. |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
EP3478676A1 (en) * | 2016-06-29 | 2019-05-08 | Orion Corporation | Benzodioxane derivatives and their pharmaceutical use |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
GB201801128D0 (en) * | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
US20210355114A1 (en) * | 2018-10-24 | 2021-11-18 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
CN109293480B (zh) * | 2018-10-31 | 2020-10-09 | 陕西硕博电子材料有限公司 | 二烯丙基双酚a、制备方法及双马来酰亚胺树脂预聚物 |
KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
US11559502B2 (en) | 2019-08-26 | 2023-01-24 | Period Pill Bv | Treatment of menstrual cycle-induced symptoms |
EP4161503A2 (en) * | 2020-06-08 | 2023-04-12 | Tactogen Inc. | Advantageous benzofuran compositions for mental disorders or enhancement |
CN112121463B (zh) * | 2020-09-15 | 2022-03-22 | 烟台宁远药业有限公司 | 一种多取代苯并含氮杂环甲胺的制备方法 |
CN114890978B (zh) * | 2022-04-19 | 2023-07-25 | 宿迁医美科技有限公司 | 酚类化合物及其制备方法和应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2906757A (en) * | 1959-09-29 | Their preparation | ||
BE635203A (es) * | 1962-07-20 | |||
US3872105A (en) * | 1973-06-11 | 1975-03-18 | Merrell Inc Richard | Derivatives of 1,3-benzodioxole-2-carboxylic acid |
US4118507A (en) * | 1977-03-17 | 1978-10-03 | Shell Oil Company | Benzodioxincarboxamide lipogenesis inhibitors |
US5120758A (en) * | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
JP3454531B2 (ja) * | 1991-11-07 | 2003-10-06 | 三共株式会社 | ニトロキシアルキルアミド誘導体 |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
FR2716680B1 (fr) * | 1994-02-25 | 1996-04-05 | Adir | Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
JP3235448B2 (ja) * | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | 1,4−ベンゾジオキサン誘導体の製法 |
US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
FR2791675B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
CN100486973C (zh) * | 2002-07-29 | 2009-05-13 | 霍夫曼-拉罗奇有限公司 | 新苯并间二氧杂环戊烯类 |
US7728155B2 (en) * | 2003-10-24 | 2010-06-01 | Wyeth Llc | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
CN100540546C (zh) * | 2004-05-05 | 2009-09-16 | 弗·哈夫曼-拉罗切有限公司 | 用于调节5-ht6受体、5-ht2a受体或两者的芳基磺酰基苯并二烷 |
GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
TW200719886A (en) * | 2005-04-22 | 2007-06-01 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
AU2006239918A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combianations for the treatment or prevention of depression |
PE20061297A1 (es) * | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c |
US20060258713A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Treatment of pain |
AU2006239900A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
AU2006239917A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse |
AU2006239910A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
JP2008538573A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用 |
CN101175740A (zh) * | 2005-04-22 | 2008-05-07 | 惠氏公司 | 二氢苯并呋喃衍生物和其用途 |
MX2007013179A (es) * | 2005-04-22 | 2008-01-16 | Wyeth Corp | Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina. |
EP1874292A2 (en) * | 2005-04-24 | 2008-01-09 | Wyeth | Methods for modulating bladder function |
-
2006
- 2006-04-21 WO PCT/US2006/015201 patent/WO2006116158A1/en active Application Filing
- 2006-04-21 CN CNA2006800226232A patent/CN101218223A/zh active Pending
- 2006-04-21 US US11/409,466 patent/US20060241172A1/en not_active Abandoned
- 2006-04-21 KR KR1020077027248A patent/KR20080009295A/ko not_active Application Discontinuation
- 2006-04-21 RU RU2007139543/04A patent/RU2007139543A/ru unknown
- 2006-04-21 BR BRPI0610046-5A patent/BRPI0610046A2/pt not_active Application Discontinuation
- 2006-04-21 AU AU2006239930A patent/AU2006239930A1/en not_active Abandoned
- 2006-04-21 AR ARP060101589A patent/AR054035A1/es unknown
- 2006-04-21 PE PE2006000414A patent/PE20061335A1/es not_active Application Discontinuation
- 2006-04-21 GT GT200600159A patent/GT200600159A/es unknown
- 2006-04-21 MX MX2007013151A patent/MX2007013151A/es unknown
- 2006-04-21 EP EP06758485A patent/EP1871759A1/en not_active Withdrawn
- 2006-04-21 TW TW095114316A patent/TW200720266A/zh unknown
- 2006-04-21 JP JP2008507951A patent/JP2008538575A/ja active Pending
- 2006-04-21 CA CA002605580A patent/CA2605580A1/en not_active Abandoned
-
2007
- 2007-10-19 NI NI200700270A patent/NI200700270A/es unknown
- 2007-10-19 CR CR9459A patent/CR9459A/es not_active Application Discontinuation
- 2007-10-19 ZA ZA200709043A patent/ZA200709043B/xx unknown
- 2007-10-22 IL IL186835A patent/IL186835A0/en unknown
- 2007-11-06 NO NO20075623A patent/NO20075623L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20075623L (no) | 2008-01-17 |
JP2008538575A (ja) | 2008-10-30 |
MX2007013151A (es) | 2008-01-16 |
IL186835A0 (en) | 2008-02-09 |
RU2007139543A (ru) | 2009-05-27 |
ZA200709043B (en) | 2009-09-30 |
GT200600159A (es) | 2007-03-14 |
KR20080009295A (ko) | 2008-01-28 |
US20060241172A1 (en) | 2006-10-26 |
EP1871759A1 (en) | 2008-01-02 |
NI200700270A (es) | 2008-06-25 |
BRPI0610046A2 (pt) | 2010-05-25 |
AR054035A1 (es) | 2007-05-30 |
TW200720266A (en) | 2007-06-01 |
CR9459A (es) | 2008-02-20 |
CA2605580A1 (en) | 2006-11-02 |
CN101218223A (zh) | 2008-07-09 |
WO2006116158A1 (en) | 2006-11-02 |
AU2006239930A1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20061335A1 (es) | Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c | |
PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20050142A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida | |
PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
PE20041040A1 (es) | Compuestos derivados de amidas como inhibidores de 11-beta-hidroxiesteroide-deshidroxigenasa de tipo 1 | |
PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
ECSP055987A (es) | Derivados de heteroarilcarbamoilbenceno | |
PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
PE20070527A1 (es) | Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa | |
PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
AR058124A1 (es) | Derivados de ftalazinona como inhibidores de parp-1 | |
PE20040832A1 (es) | Derivados de indolil pirazinona | |
BRPI0606895A2 (pt) | novos compostos com efeito terapêutico | |
PE20061295A1 (es) | Derivados de acetileno | |
GB0507601D0 (en) | Compounds | |
PE20060623A1 (es) | Compuestos de sulfonamida como potenciadores del receptor de glutamato | |
PE20080889A1 (es) | Aminometil-4-imidazoles | |
ATE409179T1 (de) | Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten | |
AR045868A1 (es) | Proceso para preparar compuestos de ocarbamoilo en presencia de grupo amina activa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |